Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine.
|Number of pages||10|
|Journal||Journal of clinical oncology : official journal of the American Society of Clinical Oncology|
|Publication status||Published - 2014|